Immunovant (IMVT) Company Report

Immunovant, Inc. entered into an underwriting agreement with Leerink Partners LLC on December 10, 2025, for the issuance and sale of 26,200,000 shares of its common stock.
The shares were offered at a price of $21.00 per share.
The offering closed on December 12, 2025, generating approximately $550 million in gross proceeds before deducting underwriting discounts and other expenses.
Roivant Sciences Ltd., the company's controlling stockholder, participated in the offering.

Dec 12, 2025, 9:15 PM

Immunovant Announces $550 Million Stock Offering and Clinical Trial Updates

IMVT

Guidance Update

New Projects/Investments

Legal Proceedings

Immunovant, Inc. announced the pricing of an underwritten offering of its common stock, with anticipated gross proceeds of approximately $550 million, expected to close around December 12, 2025.
The company expects its existing cash and the proceeds from the offering to fund operating expenses and capital expenditures through the potential commercial launch of IMVT-1402 in the Graves' Disease indication.
Initial and top-line results for the potentially registrational trial of IMVT-1402 in difficult-to-treat rheumatoid arthritis (D2T RA) are expected in 2026, while top-line results for the two potentially registrational trials of IMVT-1402 in Graves' Disease are anticipated in 2027.
Immunovant has commenced discussions with HanAll regarding the potential return of certain rights for batoclimab, which could lead to a dispute, arbitration, or litigation.

Dec 11, 2025, 11:39 AM

Immunovant Announces Pricing of Common Stock Offering

IMVT

New Projects/Investments

Immunovant announced the pricing of an underwritten offering of its common stock, with anticipated gross proceeds of approximately $550 million.
The offering consists of 26.2 million shares at an offering price of $21.00 per share.
Roivant Sciences Ltd., Immunovant’s controlling stockholder, has agreed to purchase shares in the offering.
The company expects these proceeds, combined with existing cash, to fund its operations through the potential commercial launch of IMVT-1402 in the Graves’ Disease indication.
The offering is expected to close on or about December 12, 2025.

Dec 11, 2025, 6:29 AM

Immunovant Reports Q2 2026 Results, Highlights Positive Clinical Data and Strong Capital Position

IMVT

Earnings

New Projects/Investments

Legal Proceedings

Immunovant reported a strong capital position for Q2 2026 with $4.4 billion of cash and cash equivalents and no debt, alongside a $166 million loss from continuing operations, net of tax.
The company announced positive Valor data for BREPO in dermatomyositis (DM), with an NDA filing planned for the first half of next year, aiming to be the first novel oral therapeutic in DM if approved.
Durable remission data for batoclimab in Graves' disease demonstrated disease-modifying potential, and the company has initiated multiple potentially registrational trials for IMVT-1402 in various indications, with a pipeline of 11 potentially registrational trials.
Legal proceedings include a favorable marketing ruling in the Pfizer case and a jury trial in the Moderna case scheduled for March 2026. An Investor Day is scheduled for December 11 to discuss future strategy.

Nov 10, 2025, 1:00 PM

Immunovant (IMVT) Reports Strong Cash Position and Pipeline Progress in Q2 2026

IMVT

Earnings

New Projects/Investments

Legal Proceedings

Immunovant (IMVT) maintains a strong financial position with $4.4 billion in cash and cash equivalents and no debt on the balance sheet as of Q2 2026.
The NDA filing for brepocitinib in dermatomyositis (DM) is on track for the first half of 2027, supported by positive VALOR data that met all 10 ranked endpoints.
The batoclimab (IMVT-1402) program demonstrated disease-modifying potential in Graves' disease, with 17 out of 21 patients remaining responders after six months off-drug.
Upcoming catalysts include data readouts for brepocitinib in NIU and IMVT-1402 in Graves' and MG in 2027, and TED study data in the first half of 2026.
The company received a favorable marketing ruling in the Pfizer case, and the jury trial for the Moderna case is scheduled for March 2026.

Nov 10, 2025, 1:00 PM

Immunovant Reports Q2 2026 Financial Results and Provides Clinical Trial Updates

IMVT

Earnings

New Projects/Investments

Guidance Update

Immunovant reported a net loss of $126.5 million ($0.73 per common share) for the second quarter ended September 30, 2025.
As of September 30, 2025, Immunovant's cash and cash equivalents totaled approximately $521.9 million, which is expected to provide runway through the Graves' disease (GD) readout in 2027.
The company anticipates sharing topline results from both batoclimab Phase 3 thyroid eye disease (TED) studies concurrently in the first half of calendar year 2026.
Topline results are expected in calendar year 2027 from potentially registrational trials of IMVT-1402 in GD, myasthenia gravis (MG), and difficult-to-treat rheumatoid arthritis (D2T RA).